Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

ĭ

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY OF

03 FEB 27

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

. Registrant Name				
Ropes & Gray				
Address Check if different than previous	ily reported			
1301 K St. NW, Suite 800 East				
Principal Place of Business (if different from line	e 2)			
City: Washington	State/Zip (or Country) DC 20005			
. Contact Name	Telephone	E-mail (optional)	5. Senate ID#	
Thomas M. Susman	(202) 626-3920	tsusman@ropesgray.com	336	
. Client Name Self			6. House ID#	
Pfizer, Inc.			307	
INCOME OR EXPENSES - Complete Either 12. Lobbying Firms INCOME relating to lobbying activities for this reporting		13. Organizations		
		EXPENSES relating to lobbying activities for this period were:		
period was:		Less than \$10,000 \		
Less than \$10,000 □ \$10,000 or more □ ⇒ \$				
	man non on '	\$10,000 or more		
—	\$20,000.00		*	
Incom	ne (nearest \$20,000)	Expe 14. REPORTING METHOD. Chec	k box to indi	
Provide a good faith estimate, rounded to of all lobbying related income from the	the nearest \$20,000) the nearest \$20,000, e client (including all	14. REPORTING METHOD. Chec accounting method. See instructions for	k box to indic or description	
Incor	the nearest \$20,000) the nearest \$20,000, e client (including all	Expe 14. REPORTING METHOD. Chec	k box to indic for description sing LDA def nder section (
Provide a good faith estimate, rounded to of all lobbying related income from the payments to the registrant by any other	the nearest \$20,000) the nearest \$20,000, e client (including all	Experiments of the control of the co	or description sing LDA def nder section (de	

Printed Name and Title	
LD-2 (REV. 6/98)	

Registrant Name	Ropes & Gray	Client Name	Pfizer, Inc.
engaged in lobbying	VITY. Select as many co on behalf of the client du sted. Attach additional p	ring the reporting period.	et the general issue areas in which the Using a separate page for each cod
15. General issue ar	ea code MMM (o	ne per page)	
	sement for oral anti-cancer t	herapies.	
H.R. 1624; S. 913			
17. House(s) of Cor	ngress and Federal agenc	ies contacted	Check if None
U.S. House of I U.S. Senate	Representatives		
18. Name of each i	ndividual who acted as a	lobbyist in this issue area	
	Name		Covered Official Position (if applicable)
Sam Turner, Partne	r 		-Patennah-
Elizabeth Goss, Pa			
'd 80%+40d=180'		***	
	9754601	***	
(4980404)			
F. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.		***	
19. Interest of each	foreign entity in the specific	issues listed on line 16 abo	ve Check if None
	amhr.		Date 2/14/03
Signature	0/10/10		Date 2/14/03

Form LD-2 (Rev.6/98)